DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System

Dow Jones

Apr 10, 2025

By Adriano Marchese

DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system.

Shares traded 8.5% higher at $72.55.

The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes.

At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

April 10, 2025 09:13 ET (13:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2526564496"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526564496\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2526564496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-10 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526564496","market":"sg","top_or_hot":-1,"title":"DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system. \n</p>\n<p>\n  Shares traded 8.5% higher at $72.55. \n</p>\n<p>\n  The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. \n</p>\n<p>\n  At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2025 09:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-10 21:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system. \n</p>\n<p>\n  Shares traded 8.5% higher at $72.55. \n</p>\n<p>\n  The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. \n</p>\n<p>\n  At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2025 09:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2433249047.HKD","symbol_name":"THEMATICS META \"R/A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2526564496","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526564496","pubTimestamp":1744290780,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system.The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes.At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4585":"ETF&股票定投概念","DXCM":"德康医疗","BK4534":"瑞士信贷持仓","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4082":"医疗保健设备","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4504":"桥水持仓","LU1923622614.USD":"Natixis Thematics Meta R/A USD","BK4588":"碎股","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4548":"巴美列捷福持仓","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4551":"寇图资本持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC"},"translate_title":"FDA批准葡萄糖监测系统，DexCom股价在盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system. \n\n\n  Shares traded 8.5% higher at $72.55. \n\n\n  The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. \n\n\n  At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 09:13 ET (13:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}